Zoetis Inc. $ZTS Shares Bought by Brighton Jones LLC

Brighton Jones LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 24.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 6,647 shares of the company’s stock after acquiring an additional 1,298 shares during the quarter. Brighton Jones LLC’s holdings in Zoetis were worth $1,037,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Nova Wealth Management Inc. purchased a new position in Zoetis during the first quarter worth about $25,000. 1248 Management LLC purchased a new position in Zoetis in the first quarter valued at about $27,000. Saudi Central Bank purchased a new position in Zoetis in the first quarter valued at about $29,000. Cornerstone Planning Group LLC grew its position in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC grew its position in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. UBS Group cut their target price on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research note on Monday, October 20th. Finally, Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $195.00.

Zoetis Trading Up 1.1%

NYSE ZTS opened at $147.57 on Tuesday. Zoetis Inc. has a one year low of $139.34 and a one year high of $184.40. The company has a 50-day simple moving average of $148.08 and a 200-day simple moving average of $153.52. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a market capitalization of $65.40 billion, a PE ratio of 25.40, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is presently 34.42%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.